Abstract:

With increasing knowledge of the molecular subtypes and target therapy of colorectal cancer， more and more efforts have therefore focused on mitogen-activated protein kinase signaling （MAPK） pathway. V-raf murine sarcoma viral oncogene homolog B （Braf） is a principal downstream effector of MAPK pathway， and plays an important role in cancer development and progress. This article will review the role of Braf mutation in metastatic colorectal cancer， with emphasis on molecular and clinico-pathological characteristics， and current difficulties and progresses in treatment of colorectal cancer for reference.